The increasing clinical importance of alloantibodies in kidney transplantation

References

• Akalin E, O'Connell PJ. (2010). Genomics of chronic allograft injury. Kidney Inter, 78, S33–7
   Web of Science ®Google Scholar
• Ambrus JL, Pippin J, Joseph A, et al. (1993). Identification of a Cdna for a Human High-Molecular-Weight B-Cell Growth-Factor. Proc Natl Acad Sci USA, 90, 6330–4
   PubMed Web of Science ®Google Scholar
• Barnett ANR, Asgari E, Chowdhury P, et al. (2013). The use of eculizumab in renal transplantation. Clin Transplant, 27, E216–29
   PubMed Web of Science ®Google Scholar
• Barnett ANR, Hadjianastassiou VG, Mamode N. (2013). Rituximab in renal transplantation. Transplant Inter, 26, 563–75
   PubMed Web of Science ®Google Scholar
• Bartel, G, Wahrmann M, Schwaiger E, et al. (2013). Solid phase detection of C4d-fixing HLA antibodies to predict rejection in high immunological risk kidney transplant recipients. Transplant Inter, 26, 121–30
   PubMedGoogle Scholar
• Bentall A, Cornell LD, Gloor JM, et al. (2013). Five-year outcomes in living donor kidney transplants with a positive crossmatch. Amer J Transplant, 13, 76–85
   PubMed Web of Science ®Google Scholar
• Bray RA, Nolen JDL, Larsen C, et al. (2006). Transplanting the highly sensitized patient: The emory algorithm. Amer J Transplant, 6, 2307–15
   PubMed Web of Science ®Google Scholar
• Caro-Oleas JL, Gonzalez-Escribano MF, Gentil-Govantes MA, et al. (2013). Influence of donor specific HLA antibodies detected by Luminex in kidney graft survival: A multivariate analysis. Human Immunol, 74, 545–9
   PubMed Web of Science ®Google Scholar
• Coelho V, Saitovitch D, Kalil J, Silva HM. (2013). Rethinking the multiple roles of B cells in organ transplantation. Curr Opin Organ Transplant, 18, 13–21
   PubMed Web of Science ®Google Scholar
• Colvin RB, Hirohashi T, Farris AB, et al. (2010). Emerging role of B cells in chronic allograft dysfunction. Kidney Inter, 78, S13–17
   Web of Science ®Google Scholar
• Cooper JE, Gralla J, Cagle L, et al. (2011). Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation, 91, 1103–9
   PubMed Web of Science ®Google Scholar
• Cornell LD. (2013). Renal allograft pathology in the sensitized patient. Current Opinion in Organ Transplantation, 18, 327–36
   PubMed Web of Science ®Google Scholar
• Couzi L, Araujo C, Guidicelli G, et al. (2011). Interpretation of Positive Flow Cytometric Crossmatch in the Era of the Single-Antigen Bead Assay. Transplantation, 91, 527–35
   PubMed Web of Science ®Google Scholar
• de Kort H, Willicombe M, Brookes P, et al. (2013). Microcirculation inflammation associates with outcome in renal transplant patients with de novo donor-specific antibodies. Amer J Transplant, 13, 485–92
   PubMed Web of Science ®Google Scholar
• Devos JM, Gaber AO, Knight RJ, et al. (2012). Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Inter, 82, 598–604
   PubMed Web of Science ®Google Scholar
• Dieplinger G, Ditt V, Arns W, et al. (2014). Impact of de novo donor-specific HLA antibodies detected by Luminex solid-phase assay after transplantation in a group of 88 consecutive living-donor renal transplantations. Transplant Inter, 27, 60–8
   PubMed Web of Science ®Google Scholar
• Djamali A, Kaufman DD, Ellis TM, et al. (2014). Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Amer J Transplant, 14, 255–71
   PubMed Web of Science ®Google Scholar
• Djamali A, Muth BL, Ellis TM, et al. (2013). Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney Inter, 83, 1185–92
   PubMed Web of Science ®Google Scholar
• Dorje C, Midtvedt K, Holdaas H, et al. (2013). Early versus late acute antibody-mediated rejection in renal transplant recipients. Transplantation, 96, 79–84
   PubMed Web of Science ®Google Scholar
• Dunn TB, Noreen H, Gillingham K, et al. (2011). Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Amer J Transplant, 11, 2132–43
   PubMed Web of Science ®Google Scholar
• Einecke G, Sis B, Reeve J, et al. (2009). Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Amer J Transplant, 9, 2520–31
   PubMed Web of Science ®Google Scholar
• Ejaz NS, Shields AR, Alloway RR, et al. (2013). Randomized Controlled Pilot Study of B Cell-Targeted Induction Therapy in HLA Sensitized Kidney Transplant Recipients. Amer J Transplant, 13, 3142–54
   PubMed Web of Science ®Google Scholar
• El Ters M, Grande JP, Keddis MT, et al. (2013). Kidney Allograft Survival After Acute Rejection, the Value of Follow-Up Biopsies. Amer J Transplant, 13, 2334–41
   PubMedGoogle Scholar
• Everly MJ, Rebellato LM, Haisch CE, et al. (2013). Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation, 95, 410–17
   PubMed Web of Science ®Google Scholar
• Everly MJ, Rebellato LM, Haisch CE, et al. (2014). Impact of IgM and IgG3 Anti-HLA Alloantibodies in Primary Renal Allograft Recipients. Transplantation, 97, 494--501
   Google Scholar
• Everly MJ, Terasaki PI, Trivedi HL. (2012). Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation, 93, 572–7
   PubMed Web of Science ®Google Scholar
• Fehr T, Gaspert A. (2012). Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transplant Inter, 25, 623–32
   PubMed Web of Science ®Google Scholar
• Fidler SJ, Irish AB, Lim W, et al. (2013). Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. Transplant Immunol, 28, 148–53
   PubMed Web of Science ®Google Scholar
• Freitas MCS, Rebellato LM, Ozawa M, et al. (2013). The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation, 95, 1113–19
   PubMed Web of Science ®Google Scholar
• Gago M, Cornell LD, Kremers WK, et al. (2012). Kidney allograft inflammation and fibrosis, causes and consequences. Amer J Transplant, 12, 1199–207
   PubMed Web of Science ®Google Scholar
• Gaston RS, Cecka JM, Kasiske BL, et al. (2010). Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation, 90, 68–74
   PubMed Web of Science ®Google Scholar
• Gloor J, Cosio F, Lager DJ, Stegall MD. (2008). The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Amer J Transplant, 8, 1367–73
   PubMed Web of Science ®Google Scholar
• Gloor JM, DeGoey SR, Pineda AA, et al. (2003). Overcoming a positive crossmatch in living-donor kidney transplantation. Amer J Transplant, 3, 1017–23
   PubMed Web of Science ®Google Scholar
• Gloor JM, Winters JL, Cornell LD, et al. (2010). Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Amer J Transplant, 10, 582–9
   PubMed Web of Science ®Google Scholar
• Gombos P, Opelz G, Scherer S, et al. (2013). Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Amer J Transplant, 13, 2075–82
   PubMed Web of Science ®Google Scholar
• Grenzi PC, de Marco R, Silva RZR, et al. (2013). Antibodies against denatured HLA class II molecules detected in luminex-single antigen assay. Human Immunol, 74, 1300–3
   PubMed Web of Science ®Google Scholar
• Gupta A, Iveson V, Varagunam M, et al. (2008). Pretransplant donor-specific antibodies in cytotoxic negative crossmatch kidney transplants: Are they relevant? Transplantation, 85, 1200–4
   PubMed Web of Science ®Google Scholar
• Haas M, Sis B, Racusen LC, et al. (2014). Banff 2013 Meeting Report: Inclusin fo C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Amer J Transplant, 14, 272–383
   PubMed Web of Science ®Google Scholar
• Halloran PF, Pereira AB, Chang J, et al. (2013). Microarray diagnosis of antibody-mediated rejection in kidney transplant biopsies: An International Prospective Study (INTERCOM). Amer J Transplant, 13, 2865–74
   PubMed Web of Science ®Google Scholar
• Hidalgo LG, Campbell PM, Sis B, et al. (2009). De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Amer J Transplant, 9, 2532–41
   PubMed Web of Science ®Google Scholar
• Hidalgo LG, Sis B, Sellares S, et al. (2010). NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: Evidence for NK cell involvement in antibody-mediated rejection. Amer J Transplant, 10, 1812–22
   PubMed Web of Science ®Google Scholar
• Higgins R, Hathaway M, Lowe D, et al. (2007). Blood levels of donor-specific human leukocyte antigen antibodies after renal transplantation: Resolution of rejection in the presence of circulating donor-specific antibody. Transplantation, 84, 876–84
   PubMed Web of Science ®Google Scholar
• Hill GS, Nochy D, Bruneval P, et al. (2011). Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Amer Soc Nephrol, 22, 975–83
   PubMed Web of Science ®Google Scholar
• Hirai T, Kohei N, Omoto K, et al. (2012). Significance of low-level DSA detected by solid-phase assay in association with acute and chronic antibody-mediated rejection. Transplant Inter, 25, 925–34
   PubMed Web of Science ®Google Scholar
• Jordan SC, Reinsmoen N, Lai CH, et al. (2012). Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation. Transplant Proc, 44, 60–1
   PubMed Web of Science ®Google Scholar
• Kimball PM, Baker MA, Wagner MB, King A. (2011). Surveillance of alloantibodies after transplantation identifies the risk of chronic rejection. Kidney Inter, 79, 1131–7
   PubMed Web of Science ®Google Scholar
• Kinnear G, Jones ND, Wood KJ. (2013). Costimulation blockade: Current perspectives and implications for therapy. Transplantation, 95, 527–35
   PubMed Web of Science ®Google Scholar
• Lachmann N, Terasaki PI, Budde K, et al. (2009). Anti-human leukocyte antigen and donor-specific antibodies detected by luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation, 87, 1505–13
   PubMed Web of Science ®Google Scholar
• Leca N, Laftavi M. Shen L, et al. (2008). Regulation of human interleukin 14 transcription in vitro and in vivo after renal transplantation. Transplantation, 86, 336–41
   PubMed Web of Science ®Google Scholar
• Lee PC, Zhu L, Terasaki PI, Everly MJ. (2009). HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation, 88, 568–74
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Loupy A, Hill GS, et al. (2010). Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Amer Soc Nephrol, 21, 1398–406
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Loupy A, Vernerey D, et al. (2013). Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet, 381(9863), 313–19
   PubMed Web of Science ®Google Scholar
• Lefaucheur C, Suberbielle-Boissel C, Hill GS, et al. (2008). Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Amer J Transplant, 8, 324–31
   PubMed Web of Science ®Google Scholar
• Locke JE, Magro CM, Singer AL, et al. (2009). The use of antibody to complement protein c5 for salvage treatment of severe antibody-mediated rejection. Amer J Transplant, 9, 231–5
   PubMed Web of Science ®Google Scholar
• Loupy A, Lefaucheur C, Vernerey D, et al. (2013). Complement-binding anti-HLA antibodies and kidney-allograft survival. New Engl J Med, 369, 1215–26
   PubMed Web of Science ®Google Scholar
• Mackay F, Schneider P. (2009). Cracking the BAFF code. Nat Rev Immunol, 9, 491–502
   PubMed Web of Science ®Google Scholar
• Marfo K, Ling M, Bao Y, et al. (2012). Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients. Transplantation, 94, 345–51
   PubMed Web of Science ®Google Scholar
• Matas AJ, Smith JM, Skeans MA, et al. (2014). OPTN/SRTR 2012 Annual Data Report: kidney. Amer J Transplant, 14, 11–44
   PubMed Web of Science ®Google Scholar
• Matignon M, Muthukumar T, Seshan SV, et al. (2012). Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Transplantation, 94, 603–11
   PubMedGoogle Scholar
• Mengel M, Sis B, Haas M, et al. (2012). Banff 2011 Meeting Report: New concepts in antibody-mediated rejection. Amer J Transplant, 12, 563–70
   PubMed Web of Science ®Google Scholar
• Minucci PB, Grimaldi V, Casamassimi A, et al. (2011). Methodologies for anti-HLA antibody screening in patients awaiting kidney transplant: A comparative study. Exper Clin Transplant, 9, 381–6
   PubMed Web of Science ®Google Scholar
• Mittal KK, Mickey MR, Singal DP, Terasaki PI. (1968). Serotyping for homotransplantation. 18. Refinement of microdroplet lymphocyte cytotoxicity test. Transplantation, 6, 913–27
   Google Scholar
• Mohan S, Palanisamy A, Tsapepas D, et al. (2012). Donor-specific antibodies adversely affect kidney allograft outcomes. J Amer Soc Nephrol, 23, 2061–71
   PubMed Web of Science ®Google Scholar
• Montgomery RA. (2010). Renal transplantation across HLA and ABO antibody barriers: Integrating paired donation into desensitization protocols. Amer J Transplant, 10, 449–57
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Warren DS, Segev DL, Zachary AA. (2012). HLA incompatible renal transplantation. Current Opinion in Organ Transplantation, 17, 386–92
   PubMed Web of Science ®Google Scholar
• Montgomery RA, Zachary AA. (2004). Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplant, 8, 535–42
   PubMed Web of Science ®Google Scholar
• Ntokou ISA, Iniotaki AG, Kontou EN, et al. (2011). Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules. Transplant Inter, 24, 1084–93
   PubMed Web of Science ®Google Scholar
• Otten HG, Verhaar MC, Borst HPE, et al. (2012). Pretransplant donor-specific HLA Class-I and -II antibodies are associated with an increased risk for kidney graft failure. Amer J Transplant, 12, 1618–23
   PubMed Web of Science ®Google Scholar
• Pankewycz O, Leca N, Kohli R, et al. (2011). Conversion to low-dose tacrolimus or Rapamycin 3 months after kidney transplantation: A prospective, protocol biopsy-guided study. Transplant Proc, 43, 519–23
   PubMed Web of Science ®Google Scholar
• Perez-Flores I, Santiago JL, Calvo-Romero N, et al. (2013). Different impact of pretransplant anti-HLA antibodies detected by luminex in highly sensitized renal transplanted patients. Biomed Res Inter, article ID 738404
   Google Scholar
• Pestana JOM, Grinyo JM, Vanrenterghem Y, et al. (2012). Three-year outcomes from BENEFIT-EXT: A Phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Amer J Transplant, 12, 630–9
   PubMed Web of Science ®Google Scholar
• Rafiq MA, de Boccardo G, Schroppel B, et al. (2009). Differential outcomes in 3 types of acute antibody-mediated rejection. Clin Transplant, 23, 951–7
   PubMed Web of Science ®Google Scholar
• Reed EF, Rao P, Zhang Z, et al. (2013). Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Amer J Transplant, 13, 1859–70
   PubMed Web of Science ®Google Scholar
• Reinsmoen NL, Lai CH, Vo A, Jordan SC. (2012). Evolving Paradigms for desensitization in managing broadly HLA sensitized transplant candidates. Discov Med, 71, 267–73
   Google Scholar
• Renders L, Heemann U. (2012). Chronic renal allograft damage after transplantation: What are the reasons, what can we do? Curr Opin Organ Transplant, 17, 634–9
   PubMed Web of Science ®Google Scholar
• Sellares J, de Freitas DG, Mengel M, et al. (2012). Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Amer J Transplant, 12, 388–99
   PubMed Web of Science ®Google Scholar
• Sellares J, Reeve J, Loupy A, et al. (2013). Molecular diagnosis of antibody-mediated rejection in human kidney transplants. Amer J Transplant, 13, 971–83
   PubMed Web of Science ®Google Scholar
• Sis B, Campbell PM, Mueller T, et al. (2007). Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Amer J Transplant, 7, 1743–52
   PubMedGoogle Scholar
• Sis B, Mengel M, Haas M, et al. (2010). Banff ‘09 Meeting Report: Antibody mediated graft deterioration and implementation of Banff Working Groups. Amer J Transplant, 10, 464–71
   PubMed Web of Science ®Google Scholar
• Susal C, Opelz G, Morath C. (2013). Role and value of Luminex (R)-detected HLA antibodies before and after kidney transplantation. Transf Med Hemother, 40, 190–5
   PubMed Web of Science ®Google Scholar
• Susal C, Ovens J, Mahmoud K, et al. (2011). No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive luminex single-antigen testing: A Collaborative Transplant Study Report. Transplantation, 91, 883–7
   PubMed Web of Science ®Google Scholar
• Susal C, Roelen DL, Fischer G, et al. (2013). Algorithms for the determination of unacceptable HLA antigen mismatches in kidney transplant recipients. Tissue Antig, 82, 83–92
   PubMedGoogle Scholar
• Taflin C, Charron D, Glotz D, Mooney N. (2011). Immunological function of the endothelial cell within the setting of organ transplantation. Immunol Lett, 139(1–2), 1–6
   Web of Science ®Google Scholar
• Tait BD, Susal C, Gebel HM, et al. (2013). Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation. Transplantation, 95, 19–47
   PubMed Web of Science ®Google Scholar
• Terasaki PI, Cai JC. (2008). Human leukocyte antigen antibodies and chronic rejection: From association to causation. Transplantation, 86, 377–83
   PubMed Web of Science ®Google Scholar
• Thibaudin D, Alamartine E, de Filippis JP, et al. (1998). Advantage of antithymocyte globulin induction in sensitized kidney recipients: a randomized prospective study comparing induction with and without antithymocyte globulin. Nephrol Dial Transplant, 13, 711–15
   PubMed Web of Science ®Google Scholar
• Thibault-Espitia A, Foucher Y, Danger R, et al. (2012). BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies. Amer J Transplant, 12, 2754–62
   PubMed Web of Science ®Google Scholar
• Vo AA, Peng A, Toyoda M, et al. (2010). Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation, 89, 1095–102
   PubMed Web of Science ®Google Scholar
• Wiebe C, Gibson IW, Blydt-Hansen TD, et al. (2012). Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Amer J Transplant, 12, 1157–67
   PubMed Web of Science ®Google Scholar
• Yamanaga S, Watarai Y, Yamamoto T, et al. (2013). Frequent development of subclinical chronic antibody-mediated rejection within 1 year after renal transplantation with pre-transplant positive donor-specific antibodies and negative CDC crossmatches. Human Immunol, 74, 1111–18
   PubMed Web of Science ®Google Scholar
• Zhang X, Reed EF. (2009). Effect of antibodies on endothelium. Amer J Transplant, 9, 2459–65
   PubMed Web of Science ®Google Scholar